MXPA03005284A - Nuevo procedimiento para la sintesis de fenilamida del acido 5-(4-flourofenil) -1-[2-((2r, 4r)-4-hidroxi -6-oxotetrahidro -piran-2-il) -etil]-2-isopropil -4-fenil-1h -pirrol-3-carboxilico. - Google Patents

Nuevo procedimiento para la sintesis de fenilamida del acido 5-(4-flourofenil) -1-[2-((2r, 4r)-4-hidroxi -6-oxotetrahidro -piran-2-il) -etil]-2-isopropil -4-fenil-1h -pirrol-3-carboxilico.

Info

Publication number
MXPA03005284A
MXPA03005284A MXPA03005284A MXPA03005284A MXPA03005284A MX PA03005284 A MXPA03005284 A MX PA03005284A MX PA03005284 A MXPA03005284 A MX PA03005284A MX PA03005284 A MXPA03005284 A MX PA03005284A MX PA03005284 A MXPA03005284 A MX PA03005284A
Authority
MX
Mexico
Prior art keywords
pyran
fluorophenyl
tetrahydro
oxo
isopropyl
Prior art date
Application number
MXPA03005284A
Other languages
English (en)
Inventor
Donald Eugene Butler
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of MXPA03005284A publication Critical patent/MXPA03005284A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/18—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carboxylic acids, or sulfur or nitrogen analogues thereof
    • C07D295/182—Radicals derived from carboxylic acids
    • C07D295/185—Radicals derived from carboxylic acids from aliphatic carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/416—2,5-Pyrrolidine-diones with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Pyrrole Compounds (AREA)
  • Catalysts (AREA)
MXPA03005284A 2001-01-09 2001-12-27 Nuevo procedimiento para la sintesis de fenilamida del acido 5-(4-flourofenil) -1-[2-((2r, 4r)-4-hidroxi -6-oxotetrahidro -piran-2-il) -etil]-2-isopropil -4-fenil-1h -pirrol-3-carboxilico. MXPA03005284A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US26050501P 2001-01-09 2001-01-09
PCT/IB2001/002729 WO2002055519A2 (en) 2001-01-09 2001-12-27 Novel process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2r, 4r)-4-hydroxy -6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide

Publications (1)

Publication Number Publication Date
MXPA03005284A true MXPA03005284A (es) 2003-09-25

Family

ID=22989433

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA03005284A MXPA03005284A (es) 2001-01-09 2001-12-27 Nuevo procedimiento para la sintesis de fenilamida del acido 5-(4-flourofenil) -1-[2-((2r, 4r)-4-hidroxi -6-oxotetrahidro -piran-2-il) -etil]-2-isopropil -4-fenil-1h -pirrol-3-carboxilico.

Country Status (25)

Country Link
US (7) US6476235B2 (es)
EP (1) EP1353917B1 (es)
JP (2) JP4190285B2 (es)
KR (3) KR100833911B1 (es)
CN (4) CN1907984A (es)
AR (1) AR035680A1 (es)
AT (1) ATE358126T1 (es)
BR (1) BR0116739A (es)
CA (1) CA2432064C (es)
CY (1) CY1106590T1 (es)
CZ (1) CZ20031893A3 (es)
DE (1) DE60127583T2 (es)
DK (1) DK1353917T3 (es)
ES (1) ES2282200T3 (es)
HK (2) HK1060572A1 (es)
HU (1) HUP0302647A3 (es)
IL (4) IL156461A0 (es)
MX (1) MXPA03005284A (es)
PL (1) PL365283A1 (es)
PT (1) PT1353917E (es)
RU (1) RU2244714C1 (es)
TW (1) TWI293073B (es)
WO (1) WO2002055519A2 (es)
YU (1) YU49003A (es)
ZA (1) ZA200304684B (es)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7411075B1 (en) 2000-11-16 2008-08-12 Teva Pharmaceutical Industries Ltd. Polymorphic form of atorvastatin calcium
US7501450B2 (en) * 2000-11-30 2009-03-10 Teva Pharaceutical Industries Ltd. Crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
IL156055A0 (en) * 2000-11-30 2003-12-23 Teva Pharma Novel crystal forms of atorvastatin hemi calcium and processes for their preparation as well as novel processes for preparing other forms
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide
IL159719A0 (en) * 2001-07-06 2004-06-20 Teva Pharma Process for the preparation of 7-amino syn 3,5-dihydroxy heptanoic acid derivatives via 6-cyano syn 3,5-dihydroxy hexanoic acid derivatives
US20060020137A1 (en) * 2001-11-29 2006-01-26 Limor Tessler Novel crystal forms of atorvastatin hemi-calcium and processes for their preparation as well as novel processes for preparing other forms
RS20050105A (en) * 2002-08-06 2007-11-15 Warner-Lambert Company Llc., Process for preparing 5-(4-(54) fluorophenyl)-1-(2-((2r,4r)-4- hydroxy -6-oxo-tetrahydro-pyran-2-yl)ethyl)- 2-isopropyl-4- phenyl-1h-pyrrole-3- carboxylic acid phenylamide
KR100765555B1 (ko) * 2002-08-06 2007-10-09 워너-램버트 캄파니 엘엘씨 5-(4-플루오로페닐)-1-[2-((2ｒ,4ｒ)-4-히드록시-6-옥소-테트라히드로-피란-2-일)에틸]-2-이소프로필-4-페닐-1ｈ-피롤-3-카르복실산 페닐아미드의 제조 방법
EP1480943A2 (en) * 2002-11-15 2004-12-01 Teva Pharmaceutical Industries Limited Synthesis of 3,5-dihydroxy-7-pyrrol-1-yl heptanoic acids
RS20050760A (sr) * 2003-04-14 2008-04-04 Warner-Lambert Company Llc., Postupak za izradu fenilamida 5-(4- fluorofenil)-1-(2-((2r, 4r)-4-hidroksi- 6-okso-tetrahidro-piran-2-il)etil)-2- izopropil-4-fenil-1h-pirol-3- karboksilne kiseline
US7166638B2 (en) 2003-05-27 2007-01-23 Nicox S.A. Statin derivatives
US7790197B2 (en) * 2003-06-09 2010-09-07 Warner-Lambert Company Llc Pharmaceutical compositions of atorvastatin
US20050271717A1 (en) * 2003-06-12 2005-12-08 Alfred Berchielli Pharmaceutical compositions of atorvastatin
US7655692B2 (en) * 2003-06-12 2010-02-02 Pfizer Inc. Process for forming amorphous atorvastatin
US20040253305A1 (en) * 2003-06-12 2004-12-16 Luner Paul E. Pharmaceutical compositions of atorvastatin
EP1636243B1 (de) * 2003-06-13 2013-11-06 Boehringer Ingelheim International GmbH Chirale liganden zur anwendung in asymmetrischen synthesen
CN101318923A (zh) * 2003-09-17 2008-12-10 沃尼尔·朗伯有限责任公司 [R－(R*,R*)]－2－(4－氟苯基)－β,δ－二羟基－5－(1－甲基乙基)－3－苯基－4－[(苯基氨基)羰基]－1H－吡咯－1－庚酸的结晶形式
CN102030645A (zh) 2003-10-24 2011-04-27 隆萨股份公司 6,6,6-三卤-3,5-二氧代己酸酯的制备方法
US20050152323A1 (en) * 2004-01-12 2005-07-14 Vincent Bonnassieux Plug-in Wi-Fi access point device and system
SI21745A (sl) * 2004-04-09 2005-10-31 Krka, Tovarna Zdravil, D.D., Novo Mesto Polimorfi derivata 1-pirol-1-heptanojske kisline, intermediata za pripravo atorvastatina
MXPA06011987A (es) * 2004-04-16 2007-01-16 Pfizer Prod Inc Procedimiento para formar calcio de atorvastatina amorfa.
ES2739493T3 (es) 2004-05-05 2020-01-31 Pfizer Prod Inc Formas de sal de de atorvastatina con benetamina
CZ299175B6 (cs) * 2004-06-17 2008-05-07 Zentiva, A. S Zpusob stanovení enantiomerní cistoty 2-(4-fluorfenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-fenyl-4[(fenylamino)-karbonyl]-1H-pyrrol-1-heptanové kyseliny a jejích solí
AU2005263550C1 (en) * 2004-07-16 2013-01-17 Lek Pharmaceuticals D.D. Oxidative degradation products of atorvastatin calcium
EP1771412A2 (en) 2004-07-20 2007-04-11 Warner-Lambert Company LLC Crystalline forms of [r-(r*)]-2-(4-fluorophenyl)-bet a,gamma-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1h-pyrrole-1-hept anoic acid calcium salt (2:1)
JP4703649B2 (ja) * 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド 薬学的因子としてのピロール誘導体
CN101048141A (zh) 2004-10-28 2007-10-03 沃尼尔·朗伯有限责任公司 形成非晶形的阿托伐他汀的方法
JP2008521878A (ja) * 2004-12-02 2008-06-26 ワーナー−ランバート カンパニー リミテッド ライアビリティー カンパニー 非晶質アトルバスタチンの医薬組成物及びその製造のための方法
WO2006067795A2 (en) * 2004-12-23 2006-06-29 Jubilant Organosys Limited Novel polymorphic forms of atorvastatin lactone and process for preparing the same
CA2601111A1 (en) * 2005-03-14 2006-09-21 Pfizer Science And Technology Ireland Limited Preparation of an atorvastatin intermediate using a paal-knorr condensation
EP1705175A1 (en) * 2005-03-24 2006-09-27 ratiopharm GmbH Process for preparing C5 products and their use for Atorvastatin synthesis
CA2547216A1 (en) * 2005-09-21 2007-03-21 Renuka D. Reddy Process for annealing amorphous atorvastatin
GB0523637D0 (en) * 2005-11-21 2005-12-28 Avecia Pharmaceuticals Ltd Process and compounds
US8084488B2 (en) * 2005-11-21 2011-12-27 Pfizer Inc. Forms of [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid magnesium
WO2007131528A1 (en) * 2006-05-15 2007-11-22 Ratiopharm Gmbh Process for preparing c5 intermediates and their use in the preparation of n-substituted pyrrole derivatives
KR101069698B1 (ko) * 2008-08-28 2011-10-04 한국화학연구원 광학 활성을 갖는 (4ｒ, 6ｒ)-6-(2-아미노에틸)-4-하이드록시-테트라하이드로피란-2-온 유도체의 제조방법
CN101429195B (zh) * 2008-11-03 2010-12-15 华东师范大学 一种高纯度阿托伐他汀重要合成中间体的制备方法
WO2010069593A1 (en) 2008-12-19 2010-06-24 Krka, D. D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
EP2327682A1 (en) 2009-10-29 2011-06-01 KRKA, D.D., Novo Mesto Use of amphiphilic compounds for controlled crystallization of statins and statin intermediates
US9334266B2 (en) 2009-09-04 2016-05-10 The University Of Toledo Catalysts and related processes for producing optically pure beta-lactones from aldehydes and compositions produced thereby
KR100986755B1 (ko) * 2009-12-29 2010-10-08 김우진 노즐 회전장치 및 이를 갖는 분수
CN101892276B (zh) * 2010-06-12 2012-11-21 郝志艳 一种阿托伐他汀钙化合物及其新方法
EP2616454B1 (en) 2010-09-16 2015-04-15 DSM Sinochem Pharmaceuticals Netherlands B.V. Esters of hexanoic acids as intermediates for the preparation of atorvastatin
BRPI1101952B1 (pt) * 2011-04-25 2022-02-01 Universidade Estadual De Campinas - Unicamp Processo de obtenção de atorvastatina cálcica utilizando novos intermediários e atorvastatina assim obtida
CN103702982A (zh) 2011-07-01 2014-04-02 中化帝斯曼制药有限公司荷兰公司 阿托伐他汀半钙的超细晶体
EA201891817A1 (ru) * 2016-02-11 2019-07-31 Стихтинг Катхолике Юниверситейт Новый класс соединений для лечения сердечно-сосудистых заболеваний
US11513815B1 (en) 2019-05-24 2022-11-29 Hiro Systems Pbc Defining data storage within smart contracts
US11657391B1 (en) 2019-05-24 2023-05-23 Hiro Systems Pbc System and method for invoking smart contracts
US10699269B1 (en) * 2019-05-24 2020-06-30 Blockstack Pbc System and method for smart contract publishing
CN113559318B (zh) * 2021-07-05 2022-09-13 四川大学 一种促神经功能恢复的手性导电修复支架及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681893A (en) * 1986-05-30 1987-07-21 Warner-Lambert Company Trans-6-[2-(3- or 4-carboxamido-substituted pyrrol-1-yl)alkyl]-4-hydroxypyran-2-one inhibitors of cholesterol synthesis
US5245047A (en) 1988-02-22 1993-09-14 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5149837A (en) 1988-02-22 1992-09-22 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5003080A (en) 1988-02-22 1991-03-26 Warner-Lambert Company Process for trans-6-(2-(substituted-pyrrol-1-yl)alkyl)pryan-2-one inhibitors of cholesterol synthesis
US5124482A (en) 1988-02-22 1992-06-23 Warner-Lambert Company Process for trans-6-(2-substituted-pyrrol-1-yl)alkyl)pyran-2-one inhibitors of cholesterol synthesis
US5216174A (en) * 1988-02-22 1993-06-01 Warner-Lambert Co. Process for trans-6-[12-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
US5097045A (en) 1989-02-01 1992-03-17 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
FI94339C (fi) * 1989-07-21 1995-08-25 Warner Lambert Co Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
US5103024A (en) 1990-10-17 1992-04-07 Warner-Lambert Company Process for the synthesis of (4r-cis)-1,1-dimethylethyl 6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5248793A (en) 1990-10-17 1993-09-28 Warner-Lambert Company Process for the synthesis of (4R-cis)-1,1-dimethylethyl 6-iodomethyl or 6-(phenyl-substituted)sulfonyloxymethyl-2,2-dimethyl-1,3-dioxane-4-acetate
US5155251A (en) 1991-10-11 1992-10-13 Warner-Lambert Company Process for the synthesis of (5R)-1,1-dimethylethyl-6-cyano-5-hydroxy-3-oxo-hexanoate
US5298627A (en) 1993-03-03 1994-03-29 Warner-Lambert Company Process for trans-6-[2-(substituted-pyrrol-1-yl)alkyl]pyran-2-one inhibitors of cholesterol synthesis
HRP960313B1 (en) 1995-07-17 2002-08-31 Warner Lambert Co Form iii crystalline (r- (r*, r*)-2- (4-fluorophenyl) -beta-delta-hydroxy-5-(1-methylethyl) -3-phenyl-4- ((phenylamino) carbonyl -1h-pyrrole-1-heptanoic acid calcium salt (2:1)
SI0848705T1 (en) 1995-07-17 2002-04-30 Warner-Lambert Company Crystalline r-(r*,r*))-2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4- (phenylamino)carbonyl)-1h-pyrrole-1-heptanoic acid hemi calcium salt (atorvastatin)
AU2077897A (en) * 1996-04-10 1997-10-29 Warner-Lambert Company Nonpeptide endothelin antagonists with increased water solubility
US6087511A (en) 1996-07-16 2000-07-11 Warner-Lambert Company Process for the production of amorphous [R-(R*,R*)]-2-(4-fluorophenyl)-β,δ-dihydroxy-5-(1-methylethyl )-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid) calcium salt (2:1)
US5998633A (en) 1996-07-29 1999-12-07 Warner-Lambert Company Process for the synthesis of protected esters of (S)-3,4-dihydroxybutyric acid
US6476235B2 (en) * 2001-01-09 2002-11-05 Warner-Lambert Company Process for the synthesis of 5-(4-fluorophenyl)-1-[2-((2R,4R)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)-ethyl]-2-isopropyl-4-phenyl-1H-pyrrole-3-carboxylic acid phenylamide

Also Published As

Publication number Publication date
PL365283A1 (en) 2004-12-27
US6933393B2 (en) 2005-08-23
IL189358A0 (en) 2008-06-05
AU2002222430B2 (en) 2007-05-17
CN1489587A (zh) 2004-04-14
DK1353917T3 (da) 2007-06-18
CA2432064C (en) 2007-09-11
ATE358126T1 (de) 2007-04-15
CN1222521C (zh) 2005-10-12
JP2008100989A (ja) 2008-05-01
US6545153B1 (en) 2003-04-08
CY1106590T1 (el) 2012-01-25
PT1353917E (pt) 2007-05-31
HUP0302647A2 (hu) 2003-11-28
KR20060114395A (ko) 2006-11-06
KR100582326B1 (ko) 2006-05-22
US7399773B2 (en) 2008-07-15
KR100833911B1 (ko) 2008-06-03
HUP0302647A3 (en) 2009-03-30
US20050239869A1 (en) 2005-10-27
US6476235B2 (en) 2002-11-05
US20070032663A1 (en) 2007-02-08
US7183408B2 (en) 2007-02-27
CA2432064A1 (en) 2002-07-18
US20070032664A1 (en) 2007-02-08
IL189359A0 (en) 2008-06-05
CN101024626A (zh) 2007-08-29
HK1060572A1 (en) 2004-08-13
DE60127583T2 (de) 2007-12-06
JP2004520351A (ja) 2004-07-08
KR20030065594A (ko) 2003-08-06
CZ20031893A3 (cs) 2004-03-17
CN1907984A (zh) 2007-02-07
HK1084114A1 (en) 2006-07-21
US20030195353A1 (en) 2003-10-16
YU49003A (sh) 2006-05-25
EP1353917B1 (en) 2007-03-28
US20070032662A1 (en) 2007-02-08
US7361771B2 (en) 2008-04-22
KR20060015698A (ko) 2006-02-17
DE60127583D1 (de) 2007-05-10
US7371855B2 (en) 2008-05-13
CN1696129A (zh) 2005-11-16
TWI293073B (en) 2008-02-01
AR035680A1 (es) 2004-06-23
JP4190285B2 (ja) 2008-12-03
IL156461A0 (en) 2004-01-04
ES2282200T3 (es) 2007-10-16
RU2244714C1 (ru) 2005-01-20
US20020133026A1 (en) 2002-09-19
IL189357A0 (en) 2008-06-05
KR100677008B1 (ko) 2007-02-01
BR0116739A (pt) 2003-09-30
WO2002055519A2 (en) 2002-07-18
CN100351252C (zh) 2007-11-28
EP1353917A2 (en) 2003-10-22
WO2002055519A3 (en) 2002-09-19
ZA200304684B (en) 2004-06-28

Similar Documents

Publication Publication Date Title
MXPA03005284A (es) Nuevo procedimiento para la sintesis de fenilamida del acido 5-(4-flourofenil) -1-[2-((2r, 4r)-4-hidroxi -6-oxotetrahidro -piran-2-il) -etil]-2-isopropil -4-fenil-1h -pirrol-3-carboxilico.
AP2003002836A0 (en) 3-(4-Amidopyrrol-2-ylmethlidene)-2-indolinone derivatives as protein kinase inhibitors.
IL157478A0 (en) Method for the synthesis of 2', 3'-didehydronucleosides
ZA200309471B (en) Method for the preparation of escitalopram.
MXPA03006322A (es) Procedimiento mejorado para la sintesis de carbapenem.
ZA200403432B (en) Method for the preparation of escitalopram.
HK1077825A1 (en) process for preparing 5-(4-fluorophenyl)-1-Ä2-(2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethylÜ-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
MXPA03008205A (es) Procedimiento para la preparacion de compuestos de imidazol.
HK1070357A1 (en) Process for the preparation of 5-substituted isobenzofurans
DK1289527T3 (da) (+)-alfa.(2,3-dimethoxyphenyl)-1-(2-(4-fluorphenyl)-ethyl)-4-piperodonmethanol eller dets prolægemiddel til behandling af demens eller kognitiv svækkelse
AU2001237752A1 (en) An improved process for preparing simvastatin
MXPA02006102A (es) Metodo para preparar compuestos bormodifluoroaceticos.
HK1061843A1 (en) Process for cis-1-(2-(4-(6-methoxy-2-phenyl-1,2,3,4-tetrahydronape ethyl) pyrrolidine
MXPA03008211A (es) Predispersiones, proceso para su preparacion, composiciones para las mismas, proceso para la preparacion de tales composiciones..
IL155706A0 (en) Process for the preparation of (r)-5-(2-benzenesulfonylethyl)-3-(n-methylpyrrolidin-2-ylmethyl)-1h-indole
AU2003222435A8 (en) Process for the preparation of 1-(3-(dimethylamino)propyl)-1-(4-fluorophenyl)- 1,3-dihydro-5-isobenzofuran carbonitrile
ZA200309542B (en) Process for determining the biomechanical compatibility of head equipment.
AP2005003229A0 (en) Process for preparing of paclitaxel.
WO2004089894A8 (en) Process for preparing 5-(4-fluorophenyl)-1-[2-((2r,4r)-4-hydroxy-6-oxo-tetrahydro-pyran-2-yl)ethyl]-2-isopropyl-4-phenyl-1h-pyrrole-3-carboxylic acid phenylamide
HUP0303969A2 (hu) Eljárás 2-[5-(4-fluorfenil)-3-piridilmetilaminometil] kromán előállítására
MXPA03009210A (es) PROCEDIMIENTO PARA LA PREPARACIoN DE OXABISPIDINAS.
AU2003289546A1 (en) Process for preparing simvastatin.
HK1051190A1 (en) Process for the preparation of 2-(4-alkyl-1-piperazinyl-benzaldehyde and -benzylidenyl compounds.
HK1060732A1 (en) Process for preparing distamycin derivatives.
ITTO20010934A0 (it) Macchina per la composizione di tappi incollati.

Legal Events

Date Code Title Description
FG Grant or registration